VIDEO: Magrolimab plus azacitidine promising for high-risk myelodysplastic syndrome
Click Here to Manage Email Alerts
CHICAGO — In a video interview, David Andrew Sallman, MD, discussed results from the final analysis of magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes presented at ASCO Annual Meeting.
Sallman, myeloid section head at Moffitt Cancer Center, told Healio that over a median follow-up of 17 months, about three quarters of patients in the study are responding, with a true complete response rate in the 30 to 40 percentile range. Also, the overall survival was not met in the total cohort.
“This was a biased, high-risk group of patients, actually 26% were TP53-mutant. So, if we look at wild type to start with, actually over 60% of patients were still alive at data cut off,” he said. “The median survival of patients [with TP53 mutations] was 16 months. Although that’s still a challenge, it’s about 6 months better than any cohort to date as far as P53-mutant, high-risk disease. This data supports the ongoing, pivotal ENHANCE trial, which is a double-blind, placebo-controlled trial looking at doublet vs. single-agent therapy.”
Collapse
Sallman DA, et al. Abstract 7017. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Click Here to Manage Email Alerts